Yonghe Medical Group Co Ltd

Yonghe Medical Group Co Ltd maintains a strong liquidity position with CNY 698.99 million in cash and equivalents, supporting a current ratio of 1.55. The company's price-to-book ratio of 1.36 and price-to-tangible-book ratio of 1.36 indicate a moderate valuation relative to its book value. The company's profitability is reflected in a return on equity (ROE) of 9.35% and a return on assets (ROA) of 4.33%. These metrics are in line with the industry's preferred metrics for healthcare service providers, indicating efficient use of equity and assets. Yonghe Medical Group Co Ltd's revenue is primarily concentrated in the domestic market, with no disclosed international operations. The company's brand matrix includes Yonghe Hair Transplant, Svenson, Yonghe Fa Zhi Chu, and Harvard, which collectively serve a diverse range of hair-related healthcare services. The company's growth trajectory is supported by a revenue of CNY 1.81 billion and a net income of CNY 73.71 million. Analysts have set a mean price target of CNY 2.46, suggesting a potential upside from the current market price of CNY 2.04. The risk assessment for Yonghe Medical Group Co Ltd indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its debt-to-equity ratio of 0.62 suggests a conservative capital structure. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core hair-related healthcare services, with no disclosed major new initiatives or strategic shifts.